Nkcfo LLC Invests $460,000 in Neuronetics, Inc. (NASDAQ:STIM)

Key Points

• Nkcfo LLC has acquired a new stake of 125,000 shares in Neuronetics, Inc., worth approximately $460,000 as of the latest SEC filing.
• Neuronetics reported earnings of ($0.21) EPS for the last quarter, missing the consensus estimate and showing a revenue of $31.98 million.
• Insider Stephen Furlong sold 193,460 shares of Neuronetics, reducing his ownership by 31.71% in a transaction valued at over $800,000.

Nkcfo LLC bought a new position in shares of Neuronetics, Inc. (NASDAQ:STIM - Free Report) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 125,000 shares of the company's stock, valued at approximately $460,000. Nkcfo LLC owned 0.19% of Neuronetics at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in the business. Larson Financial Group LLC acquired a new stake in Neuronetics during the 1st quarter worth approximately $25,000. Geode Capital Management LLC raised its holdings in Neuronetics by 2.8% during the 4th quarter. Geode Capital Management LLC now owns 314,076 shares of the company's stock worth $506,000 after purchasing an additional 8,466 shares during the last quarter. KPP Advisory Services LLC bought a new position in Neuronetics during the 1st quarter worth approximately $37,000. Presidio Capital Management LLC bought a new position in Neuronetics during the 1st quarter worth approximately $44,000. Finally, Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new position in Neuronetics during the 1st quarter worth approximately $61,000. 53.59% of the stock is currently owned by institutional investors and hedge funds.

Neuronetics Trading Up 2.9%

Neuronetics stock traded up $0.13 during mid-day trading on Thursday, hitting $4.57. 378,528 shares of the stock were exchanged, compared to its average volume of 1,175,008. The company has a quick ratio of 2.28, a current ratio of 2.44 and a debt-to-equity ratio of 1.40. Neuronetics, Inc. has a 12 month low of $0.52 and a 12 month high of $5.92. The firm's fifty day simple moving average is $3.77 and its two-hundred day simple moving average is $3.89. The stock has a market capitalization of $302.12 million, a price-to-earnings ratio of -3.49 and a beta of 1.85.

Neuronetics (NASDAQ:STIM - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.08). Neuronetics had a negative return on equity of 174.15% and a negative net margin of 53.67%. The firm had revenue of $31.98 million for the quarter, compared to the consensus estimate of $29.07 million. Analysts forecast that Neuronetics, Inc. will post -1.13 EPS for the current year.

Insider Transactions at Neuronetics

In other Neuronetics news, EVP Stephen Furlong sold 193,460 shares of the business's stock in a transaction on Monday, May 12th. The shares were sold at an average price of $4.27, for a total transaction of $826,074.20. Following the completion of the sale, the executive vice president owned 416,593 shares in the company, valued at approximately $1,778,852.11. The trade was a 31.71% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 8.70% of the company's stock.

Neuronetics Company Profile

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.